JP2024525789A5 - - Google Patents

Info

Publication number
JP2024525789A5
JP2024525789A5 JP2024502009A JP2024502009A JP2024525789A5 JP 2024525789 A5 JP2024525789 A5 JP 2024525789A5 JP 2024502009 A JP2024502009 A JP 2024502009A JP 2024502009 A JP2024502009 A JP 2024502009A JP 2024525789 A5 JP2024525789 A5 JP 2024525789A5
Authority
JP
Japan
Application number
JP2024502009A
Other languages
Japanese (ja)
Other versions
JPWO2023288338A5 (https=
JP2024525789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073862 external-priority patent/WO2023288338A2/en
Publication of JP2024525789A publication Critical patent/JP2024525789A/ja
Publication of JP2024525789A5 publication Critical patent/JP2024525789A5/ja
Publication of JPWO2023288338A5 publication Critical patent/JPWO2023288338A5/ja
Withdrawn legal-status Critical Current

Links

JP2024502009A 2021-07-16 2022-07-18 細胞ベースの療法のためのポリシストロニックベクター Withdrawn JP2024525789A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163222954P 2021-07-16 2021-07-16
US63/222,954 2021-07-16
US202163282961P 2021-11-24 2021-11-24
US63/282,961 2021-11-24
PCT/US2022/073862 WO2023288338A2 (en) 2021-07-16 2022-07-18 Polycistronic vectors for cell-based therapies

Publications (3)

Publication Number Publication Date
JP2024525789A JP2024525789A (ja) 2024-07-12
JP2024525789A5 true JP2024525789A5 (https=) 2025-07-17
JPWO2023288338A5 JPWO2023288338A5 (https=) 2025-07-17

Family

ID=84919770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502009A Withdrawn JP2024525789A (ja) 2021-07-16 2022-07-18 細胞ベースの療法のためのポリシストロニックベクター

Country Status (9)

Country Link
US (1) US20250122529A1 (https=)
EP (1) EP4370699A4 (https=)
JP (1) JP2024525789A (https=)
KR (1) KR20240046833A (https=)
AU (1) AU2022312508A1 (https=)
CA (1) CA3224974A1 (https=)
IL (1) IL310099A (https=)
MX (1) MX2024000713A (https=)
WO (1) WO2023288338A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024216143A1 (en) * 2023-04-14 2024-10-17 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function
WO2024233887A1 (en) * 2023-05-10 2024-11-14 Science Corporation A hypoimmunogenic cell and methods of generation thereof
AU2024328949A1 (en) * 2023-08-23 2026-03-12 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
CN116987699B (zh) * 2023-09-05 2024-08-27 深圳市艾迪贝克生物医药有限公司 用于制备通用型car-t细胞的基因片段、其工具系统及应用
WO2025151838A1 (en) * 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3498824A1 (en) * 2013-04-26 2019-06-19 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
EP3418379B1 (en) * 2013-09-18 2020-12-09 Kymab Limited Methods, cells & organisms
AU2017269364B2 (en) * 2016-05-25 2023-08-31 Salk Institute For Biological Studies Compositions and methods for organoid generation and disease modeling
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
US20210308183A1 (en) * 2018-07-17 2021-10-07 The Regents Of The University Of California Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells
SG11202104524YA (en) * 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
EP3883955A1 (en) * 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
WO2020183131A1 (en) * 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
CA3194577A1 (en) * 2020-10-09 2022-04-14 Sonja SCHREPFER Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent

Similar Documents

Publication Publication Date Title
JP2024525789A5 (https=)
BR202022005961U2 (https=)
BY13176U (https=)
CN307044383S (https=)
CN307049010S (https=)
CN307048202S (https=)
CN307047794S (https=)
CN307046885S (https=)
CN307046662S (https=)
CN307046320S (https=)
CN307046288S (https=)
CN307046229S (https=)
CN307045977S (https=)
CN307045947S (https=)
CN307045392S (https=)
CN307045312S (https=)
CN307045298S (https=)
CN307044931S (https=)
CN307044420S (https=)
BY23963C1 (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)